Assessment of the efficacy of firocoxib (Previcox®) and grapiprant (Galliprant®) in an induced model of acute arthritis in dogs

Table 1 Group mean (minimum-maximum) lameness ratios in untreated control dogs, and in dogs treated with either firocoxib or grapiprant

Time (hours post induction)	Control	Firocoxib	Grapriprant
Experiment 1 - treatments administered 2 h prior to induction of arthritis
1.5	0.49 (0.00–0.89)^a	0.90 (0.73–0.99)	0.76 (0.00–1.05)^b
3	0.00 (0.00–0.00)^c	0.86 (0.75–0.98)^c	0.26 (0.00–0.83)^d
5	0.00 (0.00–0.00)^c	0.80 (0.00–1.04)^c	0.00 (0.00–0.00)^d
7	0.00 (0.00–0.00)^c	0.95 (0.69–1.05)^c	0.00 (0.00–0.00)^d
10	0.00 (0.00–0.00)^c	1.06 (0.98–1.17)^c	0.16 (0.00–0.98)^d
Experiment 2 - treatments administered 14 h prior to induction of arthritis
1.5	0.28 (0.00–0.66)^a	0.75 (0.00–0.97)	0.61 (0.00–1.02)^b
3	0.00 (0.00–0.00)	0.36 (0.00–0.84)	0.00 (0.00–0.65)
5	0.00^d (0.00–0.00)^d	0.45 (0.00–0.99)^d	0.00 (0.00–0.00)^e
7	0.00 (0.00–0.00)^c	0.80 (0.00–1.07)^c	0.00 (0.00–0.00)^d
10	0.35 (0.00–0.87)^f	0.91 (0.66–1.05)^f	0.00 (0.00–0.00)^g

Different superscripts in the same row indicate statistically significant differences: a,b p = 0.026; c,d p < 0.001; e,d p = 0.033; f,g p ≤ 0.006

ISSN: 1746-6148